NCT02246660View on ClinicalTrials.gov

RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Peripheral Arterial Disease
Interventions
DRUG

Resveratrol

"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."

DRUG

Placebo

Placebo will be taken orally for 6 months.

Trial Locations (1)

60611

Northwestern University Feinberg School of Medicine, Chicago

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Northwestern University

OTHER

NCT02246660 - RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial) | Biotech Hunter | Biotech Hunter